Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTWAWGX4)

• DOT Name: Beta-galactosidase-1-like protein 3 (GLB1L3)
• Synonyms: EC 3.2.1.-
• Gene Name: GLB1L3
• UniProt ID: GLBL3_HUMAN
• EC Number: 3.2.1.-
• Pfam ID: PF21317 ; PF21467 ; PF01301
• Sequence:
  MKSPPLLSPCLSWKRMAGIFFLPFISSGFAPRFKQEENFMLGRAHPSQPRFNWSHLTPLE
  LKNRSVGLGTESTGRGKPHFTLEGHKFLIFGGSIHYFRVPREYWRDRLLKLKACGFNTVT
  TYVPWNLHEPERGKFDFSGNLDLEAFVLMAAEIGLWVILRPGRYICSEMDLGGLPSWLLQ
  DPRLLLRTTNKSFIEAVEKYFDHLIPRVIPLQYRQAGPVIAVQVENEYGSFNKDKTYMPY
  LHKALLRRGIVELLLTSDGEKHVLSGHTKGVLAAINLQKLHQDTFNQLHKVQRDKPLLIM
  EYWVGWFDRWGDKHHVKDAKEVEHAVSEFIKYEISFNVYMFHGGTNFGFMNGATYFGKHS
  GIVTSYDYDAVLTEAGDYTEKYLKLQKLFQSVSATPLPRVPKLPPKAVYPPVRPSLYLPL
  WDALSYLNEPVRSRQPVNMENLPINNGSGQSYGLVLYEKSICSGGRLRAHAHDVAQVFLD
  ETMIGILNENNKDLHIPELRDCRYLRILVENQGRVNFSWQIQNEQKGITGSVSINNSSLE
  GFTIYSLEMKMSFFERLRSATWKPVPDSHQGPAFYCGTLKAGPSPKDTFLSLLNWNYGFV
  FINGRNLGRYWNIGPQKTLYLPGVWLHPEDNEVILFEKMMSGSDIKSTDKPTL
• Reactome Pathway:
  HS-GAG degradation (R-HSA-2024096)
  Glycosphingolipid catabolism (R-HSA-9840310)
  Keratan sulfate degradation (R-HSA-2022857)

Molecular Interaction Atlas (MIA) of This DOT

6 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the expression of Beta-galactosidase-1-like protein 3 (GLB1L3).	[1]
Niclosamide	DMJAGXQ	Approved	Niclosamide decreases the expression of Beta-galactosidase-1-like protein 3 (GLB1L3).	[2]
SNDX-275	DMH7W9X	Phase 3	SNDX-275 increases the expression of Beta-galactosidase-1-like protein 3 (GLB1L3).	[3]
Belinostat	DM6OC53	Phase 2	Belinostat increases the expression of Beta-galactosidase-1-like protein 3 (GLB1L3).	[3]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A increases the expression of Beta-galactosidase-1-like protein 3 (GLB1L3).	[5]
Milchsaure	DM462BT	Investigative	Milchsaure decreases the expression of Beta-galactosidase-1-like protein 3 (GLB1L3).	[6]

1 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene decreases the methylation of Beta-galactosidase-1-like protein 3 (GLB1L3).	[4]

References

• [1] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [2] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [3] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [4] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [5] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [6] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.